$330 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 80 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 56.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPRD S&P Biotech ETFcall | $21,906,000 | – | 300,000 | +100.0% | 6.64% | – |
| IMGN | Sell | ImmunoGen Incequities | $20,748,993 | -22.6% | 1,307,435 | -7.9% | 6.29% | -24.1% |
| MORF | Buy | Morphic Holding Incequities | $13,535,892 | -6.4% | 590,829 | +134.2% | 4.10% | -8.3% |
| MRUS | Sell | Merus NVequities | $11,790,000 | -24.0% | 500,000 | -15.1% | 3.58% | -25.5% |
| New | Soleno Therapeutics Incequities | $10,918,700 | – | 370,000 | +100.0% | 3.31% | – | |
| ITCI | Buy | Intra-Cellular Therapies Incequities | $10,872,746 | -13.6% | 208,730 | +5.0% | 3.30% | -15.3% |
| AKRO | Sell | Akero Therapeutics Inccall | $10,116,000 | -8.4% | 200,000 | -15.4% | 3.07% | -10.2% |
| CBAY | Buy | CymaBay Therapeutics Incequities | $8,796,900 | +402.1% | 590,000 | +268.8% | 2.67% | +392.1% |
| MRTX | Buy | Mirati Therapeutics Incequities | $8,712,000 | +164.4% | 200,000 | +119.3% | 2.64% | +159.2% |
| PSTX | Buy | Poseida Therapeutics Incequities | $8,491,804 | +63.8% | 3,567,985 | +21.1% | 2.58% | +60.5% |
| KRYS | Sell | Krystal Biotech Incequities | $8,297,596 | -40.6% | 71,531 | -39.9% | 2.52% | -41.7% |
| BIIB | Buy | Biogen Idec Incequities | $7,214,014 | -5.7% | 28,069 | +4.5% | 2.19% | -7.6% |
| URGN | New | Urogen Pharma Ltdequities | $7,129,451 | – | 508,883 | +100.0% | 2.16% | – |
| UTHR | Buy | United Therapeutics Corpequities | $7,097,739 | +7.1% | 31,424 | +4.6% | 2.15% | +4.9% |
| PRAX | Buy | Praxis Precision Medicines Incequities | $7,041,643 | +76.1% | 4,117,920 | +18.5% | 2.14% | +72.6% |
| ORIC | Sell | Oric Pharmaceuticals Incequities | $6,796,237 | -39.6% | 1,123,345 | -22.6% | 2.06% | -40.8% |
| CRNX | New | Crinetics Pharmaceuticals Incequities | $6,542,800 | – | 220,000 | +100.0% | 1.98% | – |
| MRTX | Mirati Therapeutics Inccall | $6,534,000 | +20.6% | 150,000 | 0.0% | 1.98% | +18.2% | |
| COGT | Buy | Cogent Biosciences Incequities | $6,350,877 | -13.5% | 651,372 | +5.1% | 1.93% | -15.2% |
| MRSN | Buy | Mersana Therapeutics Incequities | $6,350,000 | +93.0% | 5,000,000 | +400.0% | 1.92% | +89.1% |
| RYTM | Buy | Rhythm Pharmaceuticals Incequities | $5,972,811 | +211.8% | 260,537 | +124.3% | 1.81% | +205.4% |
| MGNX | Buy | MacroGenics Incequities | $5,890,976 | -9.4% | 1,264,158 | +4.0% | 1.79% | -11.2% |
| BCRX | Buy | BioCryst Pharmaceuticals Incequities | $5,605,031 | +4.6% | 791,671 | +4.0% | 1.70% | +2.5% |
| NVO | New | Novo Nordisk A/Sequities | $5,456,400 | – | 60,000 | +100.0% | 1.65% | – |
| AKRO | New | Akero Therapeutics Incput | $5,391,828 | – | 106,600 | +100.0% | 1.64% | – |
| VCYT | Buy | Veracyte Incequities | $5,349,620 | -8.5% | 239,571 | +4.4% | 1.62% | -10.3% |
| KALV | New | KalVista Pharmaceuticals Inccall | $5,107,752 | – | 530,400 | +100.0% | 1.55% | – |
| GOSS | New | Gossamer Bio Incequities | $5,105,287 | – | 6,130,268 | +100.0% | 1.55% | – |
| OLMA | Buy | Olema Pharmaceuticals Incequities | $5,036,342 | +42.8% | 407,801 | +4.4% | 1.53% | +40.0% |
| HUM | New | Humana Incequities | $4,865,200 | – | 10,000 | +100.0% | 1.48% | – |
| VRTX | Buy | Vertex Pharmaceuticals Incequities | $4,786,641 | +3.2% | 13,765 | +4.5% | 1.45% | +1.2% |
| GILD | Buy | Gilead Sciences Incequities | $4,705,408 | +1.0% | 62,789 | +3.9% | 1.43% | -1.0% |
| PLRX | Buy | Pliant Therapeutics Incequities | $4,342,092 | +123.4% | 250,409 | +133.4% | 1.32% | +119.1% |
| New | Caribou Biosciences Incequities | $4,267,517 | – | 892,786 | +100.0% | 1.29% | – | |
| IMGN | New | ImmunoGen Inccall | $3,967,500 | – | 250,000 | +100.0% | 1.20% | – |
| TELA | Buy | Tela Bio Incequities | $3,923,768 | -7.0% | 490,471 | +17.8% | 1.19% | -8.8% |
| INSM | Buy | Insmed Incequities | $3,797,272 | +24.6% | 150,387 | +4.1% | 1.15% | +22.1% |
| MIRM | Buy | Mirum Pharmaceuticals Incequities | $3,479,602 | +26.4% | 110,114 | +3.5% | 1.06% | +24.0% |
| CBAY | New | CymaBay Therapeutics Inccall | $2,982,000 | – | 200,000 | +100.0% | 0.90% | – |
| RVPH | New | Reviva Pharmaceuticals Holdings Incput | $2,752,320 | – | 564,000 | +100.0% | 0.84% | – |
| Buy | Zura Bio Ltdequities | $2,666,664 | +103.3% | 404,040 | +152.5% | 0.81% | +99.3% | |
| TERN | Sell | Terns Pharmaceuticals Incequities | $2,515,000 | -52.1% | 500,000 | -16.6% | 0.76% | -53.0% |
| New | Molecular Templates Incequities | $2,241,123 | – | 354,608 | +100.0% | 0.68% | – | |
| KALV | Sell | KalVista Pharmaceuticals Incequities | $2,204,634 | -66.0% | 228,934 | -68.2% | 0.67% | -66.7% |
| TRVI | Buy | Trevi Therapeutics Incequities | $2,021,765 | -4.5% | 927,415 | +4.7% | 0.61% | -6.4% |
| KOD | New | Kodiak Sciences Incequities | $2,006,030 | – | 1,114,461 | +100.0% | 0.61% | – |
| CERS | Buy | Cerus Corpequities | $1,950,302 | -31.6% | 1,203,890 | +3.9% | 0.59% | -32.9% |
| XENE | Sell | Xenon Pharmaceuticals Incequities | $1,844,503 | -52.0% | 53,996 | -45.9% | 0.56% | -52.9% |
| EVGN | Buy | Evogene Ltdequities | $1,818,150 | +1599.2% | 3,100,000 | +3000.0% | 0.55% | +1569.7% |
| NTLA | Buy | Intellia Therapeutics Incequities | $1,676,429 | -19.2% | 53,018 | +4.2% | 0.51% | -20.9% |
| AKRO | Sell | Akero Therapeutics Incequities | $1,584,975 | -85.9% | 31,336 | -87.0% | 0.48% | -86.2% |
| ACRS | Sell | Aclaris Therapeutics Inccall | $1,363,150 | -79.8% | 199,000 | -69.5% | 0.41% | -80.2% |
| AVTE | New | Aerovate Therapeutics Incequities | $1,357,000 | – | 100,000 | +100.0% | 0.41% | – |
| PRTA | Sell | Prothena Corporation PLCequities | $1,284,849 | -62.2% | 26,629 | -46.4% | 0.39% | -62.9% |
| New | Roivant Sciences Ltdequities | $1,168,000 | – | 100,000 | +100.0% | 0.35% | – | |
| ALKS | Buy | Alkermes Plcequities | $1,161,155 | -7.3% | 41,455 | +3.6% | 0.35% | -9.0% |
| SRPT | Sell | Sarepta Therapeutics Incequities | $1,114,860 | -67.4% | 9,197 | -69.2% | 0.34% | -68.1% |
| MRSN | Sell | Mersana Therapeutics Inccall | $1,018,032 | -71.9% | 801,600 | -27.1% | 0.31% | -72.4% |
| ANNX | Buy | Annexon Incequities | $943,330 | -31.3% | 399,716 | +2.5% | 0.29% | -32.7% |
| ETNB | Sell | 89bio Incequities | $930,214 | -87.6% | 60,247 | -84.8% | 0.28% | -87.9% |
| BMRN | BioMarin Pharmaceutical Incequities | $884,800 | +2.1% | 10,000 | 0.0% | 0.27% | 0.0% | |
| New | Sagimet Biosciences Incequities | $880,000 | – | 100,000 | +100.0% | 0.27% | – | |
| SDGR | Sell | Schrodinger Incequities | $856,892 | -94.0% | 30,311 | -89.4% | 0.26% | -94.1% |
| VYGR | Buy | Voyager Therapeutics Incequities | $805,737 | -29.6% | 103,966 | +4.0% | 0.24% | -31.1% |
| KPTI | Buy | Karyopharm Therapeutics Incequities | $753,020 | -18.9% | 561,955 | +8.3% | 0.23% | -20.6% |
| VRDN | Buy | Viridian Therapeutics Incequities | $727,699 | -32.0% | 47,438 | +5.4% | 0.22% | -33.2% |
| PNT | Point Biopharma Global Incequities | $624,979 | -26.4% | 93,700 | 0.0% | 0.19% | -28.1% | |
| RZLT | Sell | Rezolute Incequities | $571,877 | -42.2% | 433,240 | -13.3% | 0.17% | -43.5% |
| ALGS | Aligos Therapeutics Incequities | $472,020 | -23.1% | 631,887 | 0.0% | 0.14% | -24.7% | |
| CGEN | Buy | Compugen Ltdequities | $325,675 | -13.5% | 350,188 | +6.1% | 0.10% | -14.7% |
| Sell | Eliem Therapeutics Incequities | $318,519 | -77.0% | 121,110 | -75.5% | 0.10% | -77.3% | |
| RLMD | New | Relmada Therapeutics Incequities | $300,000 | – | 100,000 | +100.0% | 0.09% | – |
| SNDX | Syndax Pharmaceuticals Incequities | $290,400 | -30.6% | 20,000 | 0.0% | 0.09% | -31.8% | |
| Eloxx Pharmaceuticals Incequities | $260,101 | +23.7% | 54,075 | 0.0% | 0.08% | +21.5% | ||
| Sell | Biohaven Ltdequities | $260,100 | -45.6% | 10,000 | -50.0% | 0.08% | -46.6% | |
| CLNN | Buy | Clene Incequities | $247,950 | +12.7% | 500,000 | +100.0% | 0.08% | +10.3% |
| New | Acelyrin Incput | $233,910 | – | 23,000 | +100.0% | 0.07% | – | |
| SRRK | New | Scholar Rock Holding Corpequities | $68,948 | – | 9,711 | +100.0% | 0.02% | – |
| Rocket Pharmaceuticals Inc Wtswarrants | $17,821 | -10.5% | 104,828 | 0.0% | 0.01% | -16.7% | ||
| ACRS | New | Aclaris Therapeutics Incput | $16,440 | – | 2,400 | +100.0% | 0.01% | – |
| Exit | Fresh Tracks Therapeutics Incequities | $0 | – | -10,000 | -100.0% | -0.00% | – | |
| VRAY | Exit | Viewray Incequities | $0 | – | -100,000 | -100.0% | -0.01% | – |
| GKOS | Exit | Glaukos Corpequities | $0 | – | -1,000 | -100.0% | -0.02% | – |
| PIRS | Exit | Pieris Pharmaceuticals Incequities | $0 | – | -961,338 | -100.0% | -0.05% | – |
| GLUE | Exit | Monte Rosa Therapeutics Incequities | $0 | – | -31,156 | -100.0% | -0.07% | – |
| FGEN | Exit | FibroGen Inccall | $0 | – | -100,000 | -100.0% | -0.08% | – |
| CLDX | Exit | Celldex Therapeutics Incequities | $0 | – | -10,000 | -100.0% | -0.10% | – |
| IMTX | Exit | Immatics Nvequities | $0 | – | -30,715 | -100.0% | -0.11% | – |
| Exit | Jasper Therapeutics Incequities | $0 | – | -500,000 | -100.0% | -0.21% | – | |
| PTGX | Exit | Protagonist Therapeutics Incequities | $0 | – | -25,000 | -100.0% | -0.21% | – |
| Exit | Ventyx Biosciences Incequities | $0 | – | -25,000 | -100.0% | -0.25% | – | |
| BBIO | Exit | Bridgebio Pharma Incequities | $0 | – | -50,000 | -100.0% | -0.27% | – |
| ALLK | Exit | Allakos Incequities | $0 | – | -200,000 | -100.0% | -0.27% | – |
| RETA | Exit | Reata Pharmaceuticals Incequities | $0 | – | -12,500 | -100.0% | -0.39% | – |
| CUE | Exit | Cue Biopharma Incequities | $0 | – | -403,402 | -100.0% | -0.46% | – |
| AMAM | Exit | Ambrx Biopharma Incequities | $0 | – | -100,000 | -100.0% | -0.51% | – |
| INCY | Exit | Incyte Corpequities | $0 | – | -34,110 | -100.0% | -0.66% | – |
| ACRS | Exit | Aclaris Therapeutics Incequities | $0 | – | -219,229 | -100.0% | -0.70% | – |
| PHAT | Exit | Phathom Pharmaceuticals Incequities | $0 | – | -200,000 | -100.0% | -0.89% | – |
| ANIP | Exit | ANI Pharmaceuticals Incequities | $0 | – | -54,041 | -100.0% | -0.90% | – |
| PHVS | Exit | Pharvaris NVequities | $0 | – | -200,000 | -100.0% | -0.94% | – |
| VKTX | Exit | Viking Therapeutics Incequities | $0 | – | -258,595 | -100.0% | -1.30% | – |
| Exit | Nuvalent Incequities | $0 | – | -115,067 | -100.0% | -1.50% | – | |
| Exit | MoonLake Immunotherapeuticsequities | $0 | – | -200,000 | -100.0% | -3.16% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SILVERARC CAPITAL, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.